FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development
The FDA released draft guidance providing a framework for drug developers to validate new approach methodologies (NAMs) as alternatives to traditional animal testing.
The guidance affects drug developers, non-clinical researchers, and regulatory professionals working to bring new drugs to market using human-centric data models.
This release indicates a formal regulatory shift toward accepting non-animal data for safety and efficacy assessments. It suggests that developers who successfully validate and implement these methodologies may be able to accelerate development timelines and improve the human relevance of their data, though the rigor of required validation remains to be seen in the full guidance text.
Regulatory and toxicology teams should review the draft guidance to understand the validation requirements for NAMs and consider how human-centric data can be integrated into early-stage development to potentially reduce reliance on animal models.
The U.S. Food and Drug Administration today issued draft guidance intended to help drug developers validate new approach methodologies (NAMs) to be used instead of animal testing in drug development, and to bring safe, effective drugs to market sooner based on human-centric data.
Open in openFDA / FDA.gov